This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Osteogenic Growth Peptide (OGP)
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict NOT-RELEVANT MEDIUM
Interesting bench-science peptide for bone formation + hematopoiesis but human clinical data is essentially zero. a user in this archetype has no bone deficit, no marrow suppression, no fracture. Would change only if a small clinical trial showed safety + efficacy AND this user had a bone indication.
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
★20-30, brain-priority, high cognitive workload (this-archetype) | NOT-RELEVANT | No bone deficit. No cognitive benefit claimed. |
30-50, executive maintenance | NOT-RELEVANT | unless DEXA shows osteopenia, in which case use proven agents (vitamin D, weight-bearing exercise, possibly bisphosphonate / teriparatide / abaloparatide). |
50+, mild cognitive decline | NOT-RELEVANT | for cognition. For osteoporosis, use proven Rx options (teriparatide, abaloparatide, romosozumab, denosumab, bisphosphonates). |
Anxiety-prone | NOT-RELEVANT | — |
High athletic load, tested status | NOT-RELEVANT | for primary use; might be peripherally interesting for stress-fracture recovery but data is too thin to recommend. |
Sleep-disordered | NOT-RELEVANT | — |
Recovery-focused (post-injury, post-illness) | WATCH-LIST LOW | If a documented stress fracture or post-chemotherapy marrow recovery context — discuss with medical team. Otherwise BPC-157 / TB-500 / proper nutrition + load management have better evidence base. |
Strength/anabolic-focused | NOT-RELEVANT | No muscle-tissue effect demonstrated. |
- ★20-30, brain-priority, high cognitive workload (this-archetype)NOT-RELEVANT
No bone deficit. No cognitive benefit claimed.
- 30-50, executive maintenanceNOT-RELEVANT
unless DEXA shows osteopenia, in which case use proven agents (vitamin D, weight-bearing exercise, possibly bisphosphonate / teriparatide / abaloparatide).
- 50+, mild cognitive declineNOT-RELEVANT
for cognition. For osteoporosis, use proven Rx options (teriparatide, abaloparatide, romosozumab, denosumab, bisphosphonates).
- Anxiety-proneNOT-RELEVANT
- High athletic load, tested statusNOT-RELEVANT
for primary use; might be peripherally interesting for stress-fracture recovery but data is too thin to recommend.
- Sleep-disorderedNOT-RELEVANT
- Recovery-focused (post-injury, post-illness)WATCH-LIST LOW
If a documented stress fracture or post-chemotherapy marrow recovery context — discuss with medical team. Otherwise BPC-157 / TB-500 / proper nutrition + load management have better evidence base.
- Strength/anabolic-focusedNOT-RELEVANT
No muscle-tissue effect demonstrated.
▸ Subjective experience (deep)
Per scattered forum reports: minimal to no acute subjective effect. Some report mild well-being / "recovery" feel during use, hard to distinguish from placebo or co-administered peptides (BPC-157, TB-500).
▸ Tolerance + cycling deep dive
- No tolerance data
- Anecdotal cycles 4-6 weeks on / off — no scientific basis
▸ Stacking deep dive
Synergistic with
- In bench/animal studies: G-CSF (hematopoietic synergy), BMPs (additive osteogenic)
- Forum-claimed (low evidence): BPC-157, TB-500 for "complete recovery stack" — no rigorous data
Avoid stacking with
- Active malignancy (theoretical mitogenic concern)
- Other osteoanabolic drugs (teriparatide, abaloparatide) — no data on combination
Neutral / safe co-administration
- Cannot make safe-stacking claims given absent human data
▸ Drug interactions deep dive
None characterized in humans. Peptide cleared by proteolysis — no CYP interactions.
▸ Pharmacogenomics
None known.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Research-chem | Various peptide vendors (Pepsciences, Limitless Life when available, etc.) | $40-100 per 10 mg vial | medium | "Research only" labeling; COA quality variable |
| Compounding pharmacy | Rare; some specialized US pharmacies make OGP(10-14) for orthopedic specialists | varies | medium-high | Not a routine offering |
For the user: Don't source — no use case.
▸ Biomarkers to track (deep)
- Baseline (if ever using): P1NP, CTX, ALP, vitamin D, calcium, CBC
- During use: P1NP/CTX every 6-12 weeks; CBC monitoring given hematopoietic effects
- Post-cycle: Same panel + DEXA at 6-12 months if bone outcome desired
▸ Controversies / open debates Live debate
- Receptor identity still unresolved — biology of action depends on a Gi-coupled receptor that has not been cloned, weakening the mechanistic story.
- Translational gap: 35+ years of preclinical work without a single registered clinical trial is a red flag — suggests pharma evaluators saw obstacles (delivery, stability, IP, or efficacy that didn't translate).
- Forum confusion: Often conflated with PTH analogs (teriparatide, abaloparatide) or mistakenly classified alongside healing peptides like BPC-157. OGP is mechanistically distinct from both.
- Stability problem: Native 14-aa OGP has very short serum half-life. OGP(10-14) is more stable but still requires frequent dosing or modified analogs that don't have safety data.
▸ Verdict change log
- 2026-05-06 — Initial verdict: NOT-RELEVANT MEDIUM. Documented because user dump put it on the queue alongside BMP-2 — same "interesting bone biology" cluster, similarly inappropriate for the user profile and significantly less clinically validated than BMP-2.
▸ Open questions / gaps Open
- Any phase-1 human safety trial — there isn't one published. Until that exists, off-label biohacker use is essentially uncharted.
- Whether OGP(10-14) provides additive benefit over BPC-157 + TB-500 in soft-tissue/bone recovery context — no head-to-head data.
References
Bab I, et al. (1992) — Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity. EMBO J
foundational discovery paper
View SourceGreenberg Z, et al. (1995) — Mitogenic action of osteogenic growth peptide (OGP): role of amino and carboxy-terminal regions and characterization of primary signal transduction pathways. Biochim Biophys Acta
mechanism characterization
View SourceGabet Y, et al. (2004) — Osteogenic growth peptide modulates fracture callus structural and mechanical properties. Bone
fracture-healing animal model
View SourcePigossi SC, et al. (2016) — Role of Osteogenic Growth Peptide (OGP) and OGP(10-14) in Bone Regeneration: A Review. Int J Mol Sci
comprehensive review
View SourceHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.